Life Science & Biotech Deal Sourcing
Scientifically Screened Deal Flow for Investors
For venture capital firms, private equity funds, family offices, and corporate venture teams investing in life sciences.
Finding the right life science deal takes more than a database search. Many of the best opportunities are off-market, early, or buried inside a technical story that is hard to evaluate quickly.
KG-STEM Advisory Group finds the deals and gives you an informed first read on each one.
We source opportunities that fit your investment thesis and screen each one through both a scientific and a business lens, so your team spends its time only on the companies worth a closer look.
Venture Capital: Biotech & Life Science Startups
For VC investors, we source and evaluate early-stage biotech and life science startups, including academic spinouts and university-born technologies.
01 | Sourcing
We identify startups that match your stage, therapeutic area, modality, and geography, drawing on university technology transfer offices, research networks, accelerators, and founder relationships.
02 | Scientific Screen
We assess the strength of the science, the mechanism, the quality of the data, and the technical risks a non-specialist could miss.
03 | Market, IP & Competition
We look at the unmet need, competing approaches, comparable companies, and the strength of the intellectual property position.
04 | Clinical & Regulatory Path
We outline the likely development path, key value-inflection milestones, and the regulatory risks that could affect timing and capital needs.
Private Equity: Stable Life Science Businesses
For PE investors, we source and evaluate established, cash-generating life science companies, including:
Laboratory testing and analytical services companies
Equipment calibration, validation, and maintenance providers
Manufacturers and distributors of lab materials, reagents, and consumables
01 | Sourcing
We find owner-operated and founder-led businesses, including off-market companies, that fit your size, sector, and geography criteria.
02 | Business Screen
We review the service and product mix, customer base and concentration, recurring revenue, and available financial indicators.
03 | Operational & Regulatory Review
We assess accreditation and quality requirements (such as ISO 17025, CLIA, and FDA quality standards), technical staffing, and equipment needs, which can make or break value in technical businesses.
04 | Fit & Next Steps
We summarize why the business fits your thesis, the key risks, and the questions to answer in diligence.
What You Receive
A curated list of opportunities matched to your investment criteria
A concise one-page screen for each opportunity, covering the science or operations, market, risks, and our recommendation
Deeper evaluations on request for the opportunities you want to pursue
Regular pipeline updates, so you always know what is in the funnel
Who We Work With
Venture capital firms investing in biotech and life sciences
Private equity funds and independent sponsors
Angel groups and syndicates
Family offices
Corporate venture capital teams
Search fund investors and searchers
Why KG-STEM
Generalist deal teams often lack the scientific depth to quickly separate strong life science opportunities from weak ones, and specialist consultants can be slow and expensive. KG-STEM combines hands-on scientific experience with financial modeling and business training.
Our founder brings more than a decade of biotechnology and life-sciences experience, an M.S. in Biotechnology from Johns Hopkins University, and specialized valuation and due diligence expertise.
Engagements are offered on a flat-fee or retainer basis.
Let’s Talk About Your Thesis
Start with a free 30-minute consultation.
Tell us what you invest in and what a great deal looks like for your fund. We’ll discuss how we can help fill your pipeline.
KG-STEM Advisory Group provides research and advisory services. We are not a registered broker-dealer or investment adviser, and we do not negotiate, arrange, or execute securities transactions. Our work does not constitute legal, tax, or investment advice.